AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
28 May 2021 - 6:15AM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates
focused on emerging immune control mechanisms applicable to
inflammation and immuno-oncology indications, today announced that
Hamza Suria, chief executive officer of AnaptysBio, will present at
the Jefferies Virtual Healthcare Conference on Thursday, June 3,
2021 at 1:30 p.m. ET. The conference will be conducted virtually,
and the audio presentation will be available via:
https://wsw.com/webcast/jeff174/anab/1811646.
A live webcast of the presentation will also be available
through the investor section of the AnaptysBio website at
https://ir.anaptysbio.com/events. A replay of the webcast will be
available for 60 days following the event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company
developing first-in-class antibody product candidates focused on
unmet medical needs in inflammation. The Company’s proprietary
anti-inflammatory pipeline includes imsidolimab, its anti-IL-36R
antibody, previously referred to as ANB019, for the treatment of
dermatological inflammatory diseases, including generalized
pustular psoriasis, or GPP, EGFRi skin toxicity, ichthyosis,
hidradenitis suppurativa and acne; its anti-PD-1 agonist program,
ANB030, for treatment of certain autoimmune diseases where immune
checkpoint receptors are insufficiently activated; and its BTLA
modulator program, ANB032, which is broadly applicable to human
inflammatory diseases associated with lymphoid and myeloid immune
cell dysregulation. AnaptysBio’s antibody pipeline has been
developed using its proprietary somatic hypermutation, or SHM
platform, which uses in vitro SHM for antibody discovery and is
designed to replicate key features of the human immune system to
overcome the limitations of competing antibody discovery
technologies. AnaptysBio has also developed multiple
therapeutic antibodies in an immuno-oncology collaboration with
GSK, including an anti-PD-1 antagonist antibody (JEMPERLI
(dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab,
GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386), and
an inflammation collaboration with Bristol-Myers Squibb, including
an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in
clinical development.
Contact:Dennis MulroyAnaptysBio,
Inc.858.732.0201dmulroy@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jul 2023 to Jul 2024